Lewis S., Romano C., De Bruecker G., Murrough J.W., Shelton R., Singh J.B., Jamieson C. (in press). Analysis of clinical trial exit interview data in patients with treatment-resistant depression. The Patient. 

Kraguljac NV, Anthony T, Monroe WS, Skidmore FM, Morgan CJ, White DM, Patel N, Lahti AC. (in press). A longitudinal neurite and free water imaging study in patients with a schizophrenia spectrum disorder, Neuropsychopharmacology.

Mabry S.J., McCollum L.A., Farmer C.B., Bloom E.S. & Roberts R.C.(in press). Evidence for altered excitatory and inhibitory tone in the postmortem substantia nigra in schizophrenia. World Journal of Biological Psychiatry. doi: 10.1080/15622975.2019.1615638.

Köhler-Forsberg O., Sylvia L., Bowden C.L., Calabrese J.R., Thase M., Shelton R.C., McInnis M., Tohen M., Kocsis J.H., Ketter T.A., Friedman E.S., Deckersbach T., Ostacher M.J., Iosifescu D.V., McElroy S., Nierenberg A.A. (in press). Correlation between white blood cell count and mood-stabilizing treatment response in two bipolar disorder trials. Acta Neuropsychiatrica.

Daly E.J., Trivedi M.H., Janik A., Li H., Zhang Y., Li X., Lane R., Lim P., Duca A.R, Hough D., Thase M.E., Zajecka J., Winokur A., Divacka I., Fagiolini A., Cubała W.J., Bitter I., Blier P., Shelton R.C., Molero P., Manji H., Drevets W.C., Singh J.B. A Double-blind, Randomized Withdrawal Study of Esketamine Nasal Spray Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression (SUSTAIN-1). JAMA Psychiatry (in press).